Company / SG&A Expense
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$141.5M
FY2025
5-year range
$124.1M / $175.0M
FY2021-FY2025
Trend
-19.2%
vs FY2024
Sector context
#121 of 158
Health Care
What the data says
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s sg&a expense of $141M is lower than 77% of companies in the Health Care sector (FY2025). SG&A Expense has fluctuated over the past 10 years, ranging from $48M in FY2016 to $175M in FY2024.
Based on SEC 10-K filings.
$141M in FY2025 with a 5-year CAGR of +14.2%.
Improved from $170M to $141M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -4.2%
- 5-Year CAGR
- +14.2%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 158This company $141.5M Sector average $175.9B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +14.2%, indicating consistent growth.
- In FY2025, sg&a expense decreased 19.2% year-over-year.
- Ranks #121 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $141.5M | -19.2% |
| FY2024 | $175.0M | +3.1% |
| FY2023 | $169.8M | +5.6% |
| FY2022 | $160.9M | +29.6% |
| FY2021 | $124.1M | +70.5% |
| FY2020 | $72.8M | -3.6% |
| FY2019 | $75.5M | +18.9% |
| FY2018 | $63.5M | +7.4% |
| FY2017 | $59.1M | +23.7% |
| FY2016 | $47.8M | +23.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026